کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3000779 | 1180344 | 2006 | 14 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Consensus Guidelines: Treatment Planning and Options
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
PHNFDASF-36VASSNRIDPNPTCADPNNNTAPs - AP هاControlled release - انتشار کنترل شدهExtended release - انتشار گستردهMedical Outcomes Study 36-item Short-Form Health Survey - بررسی نتایج پزشکی بررسی 36 مورد سلامت فرم کوتاهTricyclic antidepressant - داروهای ضدافسردگی سه حلقه ایDiabetic peripheral neuropathic pain - درد نوروپاتیک محیطی دیابتیFood and Drug Administration - سازمان غذا و داروnumber needed to treat - شماره مورد نیاز برای درمانconfidence interval - فاصله اطمینانvisual analog scale - مقیاس آنالوگ بصریSelective serotonin reuptake inhibitor - مهار کننده بازجذب سروتونین انتخابیserotonin-norepinephrine reuptake inhibitor - مهار کننده بازجذب سروتونین-نوراپی نفرینSSRI - مهارکنندههای بازجذب سروتونینpostherpetic neuralgia - نورالژی پسرشپتیکdiabetic peripheral neuropathy - نوروپاتی محیطی دیابتی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Despite the number of patients affected by diabetic peripheral neuropathic pain (DPNP), little consensus exists about the pathophysiology, best diagnostic tools, and primary treatment choices. Theories about the causes of DPNP are inextricably linked with the causes of diabetic neuropathies, yet most patients with such neuropathies do not experience pain. The factors that differentiate patients with pain from those without remain unknown and are the subject of much research. When choosing treatment for patients with DPNP, physicians are confronted with a myriad of choices, none of which has been shown to be effective for all patients. This article reviews the evidence for these treatments and attempts to guide physicians in choosing those treatments based on evidence from well-designed clinical trials to support their use. Two agents, duloxetine and pregabalin, are formally approved by the Food and Drug Administration for the treatment of DPNP. In addition, several other agents, including the tricyclic class of antidepressants, have been effective in clinical trials. Ultimately, treatment choice must also include consideration of adverse effects, individual patient factors such as comorbidities, and often cost.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings - Volume 81, Issue 4, Supplement, April 2006, Pages S12-S25
Journal: Mayo Clinic Proceedings - Volume 81, Issue 4, Supplement, April 2006, Pages S12-S25
نویسندگان
Charles E. MD, Misha-Miroslav MD, Miles J. MD, Gary J. PhD, Michael R. MD, B. Eliot MD, MPA, David A. MD, FAPA (Distinguished), Gordon A. MBBS, FFA (SA), MMed, MSc, Bill H. MD, Michael J. MD,